日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease

炎症性肠病治疗相关严重感染的比较风险

期刊:Inflammatory Bowel Diseases
影响因子:4.3
doi:10.1093/ibd/izaf218
Khan, Nabeel; Sundararajan, Ramaswamy; Patel, Dhruvan; Patel, Manthankumar; Bahirwani, Janak; Mahmud, Nadim
炎症/感染
炎症
发表日期：2026
文献求助 收藏

Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study

托法替尼治疗溃疡性结肠炎患者的疗效：一项全国退伍军人事务部队列研究

期刊:American Journal of Gastroenterology
影响因子:7.6
doi:10.14309/ajg.0000000000002761
Khan, Nabeel; Sundararajan, Ramaswamy; Patel, Manthankumar; Trivedi, Chinmay; Yang, Yu-Xiao
结肠炎
肠炎
发表日期：2024
文献求助 收藏

Clinical Course of Bio Naive Ulcerative Colitis Patients Five Years After Initiation of Adalimumab in a Nationwide Cohort

全国队列研究中，初治溃疡性结肠炎患者接受阿达木单抗治疗五年后的临床病程

期刊:Crohns Colitis 360
影响因子:2.6
doi:10.1093/crocol/otae046
Sundararajan, Ramaswamy; Patel, Manthankumar; Bahirwani, Janak; Trivedi, Chinmay; Mahmud, Nadim; Khan, Nabeel
结肠炎
肠炎
发表日期：2024
文献求助 收藏

Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients

生物制剂在IBD患者感染SARS-CoV-2后2周内输注对疾病进程的影响

期刊:Clinical Gastroenterology and Hepatology
影响因子:12
doi:10.1016/j.cgh.2022.08.017
Khan, Nabeel; Patel, Manthankumar; Sundararajan, Ramaswamy
炎症/感染
SARS-CoV-2
发表日期：2023
文献求助 收藏

The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients

在全国炎症性肠病患者队列中，从原研英夫利昔单抗转换为单转换或双转换生物类似药的疗效和安全性

期刊:Crohns Colitis 360
影响因子:2.6
doi:10.1093/crocol/otab022
Khan, Nabeel; Patel, Dhruvan; Pernes, Tyler; Patel, Manthankumar; Trivedi, Chinmay; Medvedeva, Elina; Xie, Dawei; Yang, Yu-Xiao
炎症/感染
炎症
发表日期：2021
文献求助 收藏